COMPANY

Hepatx Corporation

HQ: Palo Alto, CA source · hepatx.com ↗ · West Coast

Keywords: cell therapy

Location: Palo Alto, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $149K (SBIR Phase I 5R43DK139879-02, continuation, notice Jun 23, 2026). NIH RePORTER 5R43DK139879-02 (Jun 23, 2026)
Evidence (1 event)
- Jun 23, 2026 · NIH RePORTER 5R43DK139879-02
  Organization: HEPATX CORPORATION; City/State: PALO ALTO, CA; Project number: 5R43DK139879-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 149068; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a proteomic assay for monitoring transplanted cells and tissues; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jun 23, 2026 Grant Government grant — SBIR: $149,068 (annual award, as published), announced Jun 23, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
May 13, 2025 Grant Government grant — SBIR: $175,964 (annual award, as published), announced May 13, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Last 2 years.

Jun 23, 2026 Government grant — SBIR: $149,068 (annual award, as published), announced Jun 23, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
May 13, 2025 Government grant — SBIR: $175,964 (annual award, as published), announced May 13, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Annual award amounts. Total $375K.

Aug 28, 2019 NIH award 1R43GM134809-01 FY2019: $225,024 awarded for that fiscal year; activity R43 (SBIR); PI SCHUUR, ERIC R; recipient as written: HEPATX CORPORATION, PALO ALTO, CA. Development of a process to improve mesenchyma source ↗
Sep 12, 2017 NIH award 1R43AA026475-01 FY2017: $149,699 awarded for that fiscal year; activity R43 (SBIR); PI CHAO, MARK P; recipient as written: HEPATX CORPORATION, PALO ALTO, CA. Development of regenerative medicine therapies f source ↗